Latest Payments News

Olympio Metals has entered an Option Agreement to sell its remaining Halls Creek tenements to Clutch Group, enabling a sharper focus on its flagship Dufay Cu-Au Project in Quebec.

Sipa Resources has completed the acquisition of four advanced gold exploration projects across South Australia and Western Australia, backed by a $1.75 million capital raise and the strategic appointment of industry veteran Stephen Biggins to its board.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Embelton Limited has announced a fully franked ordinary dividend of AUD 0.15 per share for the six months ending December 2024, signaling steady shareholder returns.

Embelton Limited reported a notable 25.4% decline in revenue for the half-year ended December 31, 2024, yet managed a 23% increase in net profit, underscoring effective cost controls amid a challenging construction market. The company declared an interim dividend consistent with the prior period, signaling confidence despite subdued outlook.

Evolution Mining Limited has announced a fully franked ordinary dividend of AUD 0.07 per share for the half-year ending December 2024, accompanied by a Dividend Reinvestment Plan offering a 5% discount.

Bravura Solutions Limited has announced an ordinary and special dividend totaling AUD 0.1052 per share for the financial year ending December 2024, signaling steady shareholder returns despite an unfranked payout.

Citigroup Global Markets Australia has announced a fully franked AUD 2.25 dividend for CBA CitiFirst Instalments, with trading turning ex-dividend on 19 February 2025. This aligns with the CBA Ordinary Security dividend schedule, offering investors synchronized payout timing.

Citigroup Global Markets Australia confirms a fully franked AUD 2.25 dividend for CBA CitiFirst Instalment MINIs, aligning key dates with CBA ordinary shares.

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited has reported a robust half-year financial performance for the period ending December 31, 2024, with net profit soaring 42.7% and an increased interim dividend declared.